At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MAIA MAIA Biotechnology Inc.
Pre-Mkt 12-26 09:10:48 EST
1.48
+0.12
+8.82%
盘前1.50
+0.02+1.32%
09:09 EST
High1.48Low1.35Vol546.27K
Open1.41D1 Closing1.36Amplitude9.56%
Mkt Cap54.81MTradable Cap41.94MTotal Shares37.03M
T/O786.38KT/O Rate1.93%Tradable Shares28.34M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
GlobeNewswire  ·  12-24 21:01
MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Reuters  ·  12-23
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc
Reuters  ·  12-23
Director Ngar Yee Louie Acquires Common Shares of Maia Biotechnology Inc
MAIA Biotechnology Announces $1.51 Million Private Placement
GlobeNewswire  ·  12-17
MAIA Biotechnology Announces $1.51 Million Private Placement
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
GlobeNewswire  ·  12-12
MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
Maia Biotechnology Announces First Patient Dosed in Thio-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
THOMSON REUTERS  ·  12-11
Maia Biotechnology Announces First Patient Dosed in Thio-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer
Maia Biotechnology Executives Acquire 182,445 Shares in Insider Buying Spree
Reuters  ·  12-11
Maia Biotechnology Executives Acquire 182,445 Shares in Insider Buying Spree
Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer
Reuters  ·  12-11
Maia Biotechnology Unveils Breakthrough Telomere-Targeting Therapy for Resistant Lung Cancer
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
Reuters  ·  12-10
Director Stan Smith Reports Acquisition of Maia Biotechnology Inc. Common Shares
BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And Directors
Reuters  ·  12-01
BRIEF-Maia Biotechnology Announces Open Market Purchases By CEO And Directors
Maia Biotechnology Announces Open Market Purchases by CEO and Directors
THOMSON REUTERS  ·  12-01
Maia Biotechnology Announces Open Market Purchases by CEO and Directors
Maia Biotechnology Inc - CEO Vlad Vitoc Purchases 94,300 Shares at $1.08 Each
THOMSON REUTERS  ·  12-01
Maia Biotechnology Inc - CEO Vlad Vitoc Purchases 94,300 Shares at $1.08 Each
Maia Biotechnology Inc - Board Members Purchase 88,145 Shares at $1.04 Each
THOMSON REUTERS  ·  12-01
Maia Biotechnology Inc - Board Members Purchase 88,145 Shares at $1.04 Each
Director Stan Smith Reports Acquisition of Common Shares in Maia Biotechnology Inc
Reuters  ·  12-01
Director Stan Smith Reports Acquisition of Common Shares in Maia Biotechnology Inc
CEO’s Bold Move: Major Stock Purchase at MAIA Biotechnology!
TIPRANKS  ·  11-29
CEO’s Bold Move: Major Stock Purchase at MAIA Biotechnology!
Director Cristian Luput Acquires Common Shares of Maia Biotechnology Inc
Reuters  ·  11-28
Director Cristian Luput Acquires Common Shares of Maia Biotechnology Inc
Sarawak to Host the Inaugural Asia Pacific Aerospace Conference & Exhibition (APACE 2026) at BCCK
prnewswire  ·  11-28
Sarawak to Host the Inaugural Asia Pacific Aerospace Conference & Exhibition (APACE 2026) at BCCK
Maia Biotechnology Director Stan Smith Reports Acquisition of Common Shares
Reuters  ·  11-27
Maia Biotechnology Director Stan Smith Reports Acquisition of Common Shares
Maia Biotechnology CEO Vlad Vitoc Reports Acquisition of Common Shares
Reuters  ·  11-26
Maia Biotechnology CEO Vlad Vitoc Reports Acquisition of Common Shares
MAIA Biotechnology highlights momentum of ateganosine clinical program
TIPRANKS  ·  11-21
MAIA Biotechnology highlights momentum of ateganosine clinical program

Introduction

Company Name.
MAIA Biotechnology Inc.
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
Issue price:
--